Wikidata

(Q64640062)

English

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

clinical trial

In more languages
default for all languages
No label defined

No description defined

Statements

short name
RILOMET-1 (English)
0 references
title
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG102) With Epirubicin, Cisplatin, and Capecitabine (ECX) as First-line Therapy in Advanced MET-Positive Gastric or Gastroesophageal Junction Adenocarcinoma (English)
0 references
country
Australia
0 references
Austria
0 references
Belgium
0 references
Brazil
0 references
Bulgaria
0 references
Canada
0 references
Czech Republic
0 references
Denmark
0 references
France
0 references
Germany
0 references
Greece
0 references
Hungary
0 references
Italy
0 references
Mexico
0 references
Poland
0 references
Portugal
0 references
Romania
0 references
Slovakia
0 references
South Africa
0 references
Spain
0 references
Sweden
0 references
Switzerland
0 references
Turkey
0 references
Ukraine
0 references
United Kingdom
0 references
start time
October 2012
0 references
end time
November 2014
0 references
number of participants
609
0 references
minimum age
18 year
0 references
maximum age
99 year
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q64640062&oldid=2235609272"